Monitoring blood conditions after stem cell transplantation using cell-free DNA analysis
Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation
This study is testing if analyzing cell-free DNA from blood samples can help doctors better monitor and diagnose complications like infections and graft-versus-host disease in patients who have received a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Turin, Italy Academic / other |
| Locations | 2 sites (Milan, Milan and 1 other locations) |
| Trial ID | NCT06715046 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. It aims to utilize cell-free DNA (cfDNA) profiling to monitor clinically relevant events such as graft-versus-host disease (GVHD), infections, and other complications post-transplant. By analyzing cfDNA methylation patterns, the study seeks to provide a more accurate and timely diagnosis of these conditions compared to traditional symptom-based methods. The research involves collecting blood samples for cfDNA and extracellular vesicle analysis to assess the patient's health status after transplantation.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with hematological malignancies who require allogeneic HSCT.
Not a fit: Patients who are younger than 17 years old will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier detection and better management of complications following stem cell transplantation, improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using cfDNA analysis for monitoring various conditions, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient must be affected by an hematological malignancy requiring hematopoietic stem cell transplantation (HSCT). Exclusion Criteria: * Patients can not be 17 years old or yunger
Where this trial is running
Milan, Milan and 1 other locations
- Unità di Ematologia e Trapianto di Midollo Osseo e Oncoematologia of the San Raffaele Hospital in Milan — Milan, Milan, Italy (Recruiting)
- SS Trapianto allogenico e terapie cellulari, SC Ematologia U of the Città della Salute e della Scienza Hospital — Turin, Turin, Italy (Recruiting)
Study contacts
- Study coordinator: Silvia Deaglio, MD/PhD
- Email: silvia.deaglio@unito.it
- Phone: +39 0116709535
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.